Citations

Clear

1828 citation(s) found for "Su, Emily".

PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection
Alger, Emily , Mandrekar, Sumithra J. , Yin, Jun, Yap, Christina , Yap, Christina , Yin, Jun

Mayo Clinic

Statistical Methods in Medical Research | April 30, 2026 | Volume: 35 | Issue: 6 | Pages: 1177-1198

10.1177/09622802261435969 | PMID 42057418 Get It

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology trials. Traditional trial designs aim to identify a maximum tolerated dose (MTD) by assessing patients’ dose-limiting toxicities (DLTs) – adopting traditional dose-efficacy paradigms that efficacy increases with treatment dose. With these new therapies in mind, emphasis should shift toward methodological advancements in trial designs aimed at identifying optimal doses, rather than solely determining MTDs. Incorporating patient-reported outcomes (PROs) within dose-finding oncology trials is increasingly recommended to better understand treatments’ tolerability profiles, especially given the extended tolerability assessment windows for novel immunotherapies and targeted therapies. This article introduces PRO-ADD ( P atient- R eported O utcomes A ided D ose-optimisation D esign), a modular trial design framework for dose-optimisation. We leverage this framework to optimise dosage with respect to three key outcomes – clinician-assessed DLTs, PROs and preliminary efficacy. PRO-ADD performs well at identifying the optimal dose (both efficacious and tolerable) – successfully identifying the most tolerable effective dose and avoiding escalation to larger, safe doses offering no additional efficacy benefit. As the field evolves, patient-centric dose-finding approaches incorporating PROs are crucial in advancing our understanding of treatment tolerability, and in turn, shaping the future landscape of dose-finding oncology trials.
De‐Escalating Surgery for 1–2 cm Appendiceal Neuroendocrine Tumors: A North American Multi‐Center Analysis
Miller, R., Tan, Po Hong, Saleeb, Andrew, Stucky, Chee-Chee, Bagaria, Sanjay P, Gabriel, Emmanuel , Grotz, Travis E. , Wasif, Nabil , Miller, Max , Thompson, Emily , Miller, Richard Max , Thompson, Emily R , Grotz, Travis E , Gabriel, Emmanuel M , Saleeb, Andrew G. , Thompson, Emily R., Fong, Zhi Ven , Bagaria, Sanjay P.

Mayo Clinic

Journal of Surgical Oncology | April 30, 2026 | Volume: 134 | Issue: 1 | Pages: 91-100

10.1002/jso.70274 | PMID 42057320 Get It

ABSTRACT Background and Objectives NCCN guidelines recommend right hemicolectomy (RHC) for appendiceal neuroendocrine tumors (aNETs) > 2 cm and observation for < 1 cm. However, optimal surgical management of 1–2 cm tumors remains controversial. This study compared long‐term survival and recurrence between patients undergoing RHC versus appendectomy (APY) for 1–2 cm aNETs. Methods Patients with pathologically confirmed 1–2 cm aNETs treated at three Mayo Clinic sites (1972–2024) were included. Primary outcomes were recurrence and all‐cause mortality after resection. Associations with lymph node (LN) metastasis were assessed in patients with lymphadenectomy. Results Sixty‐five patients were identified: 29 (45%) underwent APY, 35 (54%) RHC, and one ileocecectomy. Median age at diagnosis was 39 years; 71% were female and 94% white. LN positivity was 15.2% for tumors with nodes examined. Tumor size > 1.5 cm, stage T3/T4, and lymphovascular invasion were not associated with nodal metastasis. No survival differences were observed between APY and RHC. LN positivity did not impact survival. No recurrences occurred during a median follow‐up of 6.25 years (IQR 2.44–12.63). Conclusions Among patients with 1–2 cm aNETs, RHC conferred no survival benefit over APY. Absence of recurrence and the limited prognostic value of nodal disease suggest APY alone may suffice for this population.
Deriving target exposure indices for common radiography exams based on automatic exposures of flat‐field phantoms
Hoerner, Matthew , Marshall, Emily L. , Hulme, Katie , Tao, Ashley , Alshehri, Suha, Long, Zaiyang , Macdonald, Erin , Scilla, Kathleen, Tsalafoutas, Ioannis, Long, Zaiyang , Marshall, Emily , AlKhazzam, Shady , Tsalafoutas, Ioannis A.

Mayo Clinic

Journal of Applied Clinical Medical Physics | April 29, 2026 | Volume: 27 | Issue: 5 | Pages: No page available

10.1002/acm2.70562 | PMID 42050800 Get It

Abstract Background The IEC exposure index (EI), deviation index (DI), and target exposure index (EI T ), represent critical standardized metrics for the evaluation of exposure and quality in radiographic imaging. Purpose This work develops and validates a systematic procedure to estimate the EI T for eight of the most common radiography imaging protocols utilizing automatic exposure control (AEC) from measurements acquired under reference conditions. Methods A model was developed to define the relationship between a systems AEC logic, and an estimation of the EI under flat‐field conditions (EIFFC). Separately, clinical data and acquisition protocol information for resultant EI during patient studies were also collected for the eight protocols studied: Chest posteroanterior (PA), Chest lateral, Abdomen anteroposterior (AP), Pelvis AP, L‐Spine AP, C‐Spine AP, T‐Spine AP, and Ribs AP. Data were collected from 41 x‐ray units spanning seven institutions. For each protocol on each unit the EIFFC was computed based on the acquisition protocol, as well as median EI from clinical exams to produce a scaling factor (SF). Kruskal–Wallis statistical tests were used to compare SF's between vendors and AEC cell configurations. Results SFs for eight radiographic imaging protocols have been produced per vendor and per AEC cell selection. A workflow has been established for end‐users to follow to apply these SFs to flat‐field measurements taken at their own locations to establish local EI T . Conclusions The study results show that in seven of the eight imaging protocols, the SFs for most units included in the study report SFs within 1 DI (± 25%) of their respective final vendor reported SF (218/228). The ribs protocol is the exception to this finding (n = 26). SFs have high utility for establishing EI T values on individual x‐ray units and normalizing EI value distributions for quality assurance purposes.
Whole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3
Chiles, J.W. , Rocco, Alison, Srinivasasainagendra, Vinodh, Rossiter, Harry B. , Casaburi, Richard, Thalacker-Mercer, Anna, Wells, J Michael, Wan, Emily S., Silverman, Edwin K., Cho, Michael H., Hersh, Craig P., PSATY, B, Gharib, Sina A., Gao, Yan, O’Connor, George T., Lange, Leslie A., Rich, Stephen S., Manichaikul, Ani W., Barr, R. Graham, Ortega, V E, Meyers, Deborah A., Smith, Albert V., Tiwari, Hemant K., McDonald, Merry-Lynn N. , McDonald, Merry‐Lynn , Chiles, Joe W , Casaburi, Richard , Thalacker‐Mercer, Anna Elizabeth , Wells, J. Michael , Wan, Emily S. , Silverman, Edwin K. , Cho, Michael H. , Hersh, Craig P. , Psaty, Bruce M , Gharib, Sina A. , Lange, Leslie A., Rich, Stephen S. , Manichaikul, Ani , Barr, R. Graham, Meyers, Deborah A. , Tiwari, Hemant K.

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | April 24, 2026 | Volume: 17 | Issue: 3 | Pages: No page available

10.1002/jcsm.70293 | PMID 42026014 Get It

ABSTRACT Background Chronic obstructive pulmonary disease (COPD) is associated with musculoskeletal comorbidities, including cachexia. Weight loss (WL) is the major criterion for cachexia and increases risk for mortality in COPD. Risk factors for WL in COPD are incompletely understood. We performed this whole genome sequencing (WGS) analysis to identify genetic risk variants for WL in COPD. Methods We studied 16 972 participants from the Trans‐Omics for Precision Medicine (TOPMed) Initiative and All of Us Research Program. COPD was diagnosed using spirometry in TOPMed, while diagnosis codes were used in All of Us. WL was defined as WL ≥ 5% or a final body mass index (BMI) < 20 kg/m 2 . WGS data came from white blood cells in all cohorts. Single‐variant testing was conducted on both race‐ and study‐stratified cohorts and in a cosmopolitan, ancestry‐independent manner using GENESIS in TOPMed and SAIGE in All of Us. SAIGE‐GENE+ gene‐based analyses were performed on race‐stratified and cosmopolitan cohorts. Single variant meta‐analyses were conducted using METAL within (B/AA and NHW analyses of Black/African–American and non‐Hispanic white participants, respectively) and across racial groups (COSMO). Rare variant gene‐based results were combined using Fisher's method. Transcriptomic effects were predicted using MetaXcan. We used the GWAS Catalogue to analyse for colocalization with other related traits. Results Two single variants were associated with WL in COPD among All of Us participants: one intronic variant in HCN1 in Black/African–American participants (chr5:45271359:TACACAC:T, odds ratio with 95% confidence interval (OR (CI 95 )) = 2.43(1.78–3.31), p = 1.95 × 10 −8 ) and one intergenic variant between PPP4R2 and PDZRN3 in the cosmopolitan and NHW cohorts (chr3:73345901:A:G, OR (CI 95 ) = 0.21(0.12–0.35), p = 8.84 × 10 −9 in cosmopolitan and OR (CI 95 ) = 0.18(0.10–0.33), p = 9.44 × 10 −9 in NHW). Single‐variant meta‐analysis identified two loci associated with WL in COPD: five variants within DRAIC in the B/AA meta‐analysis (lead variant chr15:69571341:A:G, OR (CI 95 ) = 1.37(1.23–1.51), p = 1.29 × 10 −9 ) and two intronic variants within RFX3 in the cosmopolitan meta‐analysis (lead variant chr9:3390983:T:C, OR (CI 95 ) = 1.50(1.31–1.73), p = 1.06 × 10 −8 ). Rare variants within RNU6‐565P (NHW analysis in All of Us; p = 2.83 × 10 −7 ) and LOC339298 (B/AA analysis in All of Us, p = 1.85 × 10 −6 ) were associated with WL in COPD. The RNU‐565P signal remained significant after combination with TOPMed results (p combined = 1.23 × 10 −6 ). MetaXcan predicted differential expression of LNC00959 in visceral adipose tissue ( p = 1.16 × 10 −6 in COSMO analysis). Colocalization analyses identified genomic associations between BMI and variants in or near DRAIC , RFX3 , PDZRN3 , and LINC00959 . Conclusions In the first WGS analysis of WL in COPD, we have identified seven novel loci. Further characterization of these loci will validate our findings and improve our understanding of the molecular pathophysiology of this condition.
Risk Factors for Incident Hyponatremia in Skilled Nursing Facility Residents: A Retrospective Cohort Study
Mead, Daniel, Mallers, Timothy, Rios, Ian, Ho, Emily, Mead, Daniel R.

Mayo Clinic

No container title available | April 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9200734/v1 Get It

Abstract Background Hyponatremia has long been recognized as a common electrolyte abnormality among skilled nursing facility (SNF) residents. In the literature, hyponatremia is associated with increases in falls, cognitive impairment, hospitalization, and increased mortality. Although many medical conditions and medications contribute to hyponatremia risk, the role of enteral feeding tubes in this population has not been well defined in clinical practice. This study examined the association between enteral feeding tube use and incident hyponatremia and evaluated selected chronic conditions and medication exposures in SNF patients. Methods We conducted a retrospective cohort study using secondary data from a suburban skilled nursing facility. Adults aged ≥ 18 years residing in the SNF with available laboratory data were included (n = 1,256). Exposures included presence of an enteral feeding tube at admission, selected chronic conditions, and high-risk medication exposures. The primary outcome was incident hyponatremia, defined as any corrected serum sodium value < 135 mEq/L occurring after admission. Relative risks were estimated using modified Poisson regression. Results Incident hyponatremia occurred in 34.6% of residents. In adjusted models, enteral feeding tubes (aRR 2.42; 95% CI 1.84–3.19), chronic kidney disease (aRR 1.87; 95% CI 1.43–2.44), and Liver Disease (aRR 1.58; 95% CI 1.20–2.07) remained the significant independent predictors. Congestive Heart Failure, ethnicity, sex, age, and high-risk medication exposure were not significantly associated with risk at the predetermined alpha = 0.01, and no significant interactions were observed between CKD, CHF, and liver disease and enteral feeding tubes on incident hyponatremia. Conclusions Hyponatremia remains a common electrolyte abnormality among SNF residents. Enteral feeding tube use was strongly associated with increased cumulative risk of incident hyponatremia. Both CKD and liver disease also pose risk of incident hyponatremia. SNF residents with enteral feeding tubes may benefit from targeted monitoring and risk stratification in long-term care settings. Clinicians should be aware of these risks while ordering water flushing of enteral tubes and assess these patients regularly for hyponatremia.
Unmasking Compound Heterozygosity in GYG1 Myopathy: Diagnostic Insights From RNA ‐Seq and Long‐Read Gen
Panwar, Deepak , Farris, Joseph , Schmidt, Danielle, Blake, Emily J., Tan, Jia W. , Naddaf, Elie, Sonnen, Joshua A. , Vairo, Filippo Pinto e, Lambert, Laura , Wierenga, Klaas J. , Klee, Eric W. , Farris, Joseph D , Sonnen, Joshua , Lambert, Laura J, Muthusamy, Karthik , Panwar, Deepak , Blake, Emily J. , Tan, Jia Wen , Naddaf, Elie , Muthusamy, Karthik

Mayo Clinic

Clinical Genetics | April 23, 2026 | Volume: 110 | Issue: 2 | Pages: 249-253

10.1111/cge.70173 | PMID 42023422 Get It

ABSTRACT Polyglucosan body myopathy type 2 (PGBM2; OMIM #616199) is an autosomal recessive myopathy caused by biallelic variants in GYG1 , which encodes glycogenin‐1. It is characterized by progressive muscle weakness and PAS‐positive, diastase‐resistant polyglucosan inclusions on muscle biopsy. We report a 64‐year‐old woman who developed progressive proximal weakness beginning in her early 50s, with polyglucosan bodies identified on muscle histopathology. Genome sequencing (GS) detected a single heterozygous pathogenic splice‐site variant, NM_004130.4( GYG1 ):c.143+3G>C. Given strong histopathologic evidence of PGBM2, GS data were reanalyzed, revealing an additional rare deep intronic variant, NM_004130.4( GYG1 ):c.7+992T>G, predicted to activate a cryptic exon. RNA sequencing (RNA‐seq) confirmed aberrant splicing from both variants, demonstrating exon 2 skipping associated with c.143+3G>C and cryptic exon inclusion caused by c.7+992T>G. Variant phasing posed a diagnostic challenge due to unavailable parental DNA, and long‐range PCR results were inconclusive. Long‐read GS definitively demonstrated that the two variants were in trans , establishing compound heterozygosity and confirming the molecular diagnosis. These findings enabled reclassification of the deep intronic variant as likely pathogenic. This case highlights the diagnostic limitations of conventional phasing approaches in adult‐onset recessive disorders and demonstrates the clinical utility of integrating genome reanalysis, RNA‐seq, and long‐read GS for resolving complex phasing challenges.
Endoscopic Marsupialization With Periodic Debridement for Petrous Apex Cholesteatoma
Hardy, Emily , Cirelli, Michael A. , Kumar, Neha, Lal, Devyani , Kumar, Nitish , Hardy, Emily G , Kumar, Nitish , Lal, Devyani , Patel, Naresh P.

Mayo Clinic

The Laryngoscope | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70574 | PMID 42011898 Get It

Features of Importance in the Nasal Exam in Rhinoplasty
Longino, Elizabeth S., Kandathil, Cherian K. , Ahmad, Jamil , Baker, Stephen B., BERKOWITZ, R. LAURENCE, Bhrany, Amit D., Friedman, Oren A., Gryskiewicz, Joe M. , Hamilton, Grant S., Knott, Daniel, Marcus, Ben C., Oyer, Sam L., Patel, Priyesh N. , Pearlman, Steven J., Rohrich, Rod J., Totonchi, Ali , Weinfeld, Adam B., Wong, Brian J.F., Most, Sam P., Marcus, Ben C , Barrera, Jose Enrique , Cobo, Roxana , Friedman, Oren A , Hamilton, Grant S., Knott, P. Daniel, Oyer, Samuel L. , Rohrich, Rod J., Shah, Manish I., Spataro, Emily A. , Wong, Brian J. F. , Most, Sam P.

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | April 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/26893614261431085 | PMID 41997893 Get It

Background: The most critical exam components in patients seeking rhinoplasty have not been established. Objective: To identify concordance among experienced rhinoplasty surgeons regarding the most important exam features for various deformities. Methods: An online questionnaire was distributed to board-certified facial plastic and plastic surgeons experienced in rhinoplasty, with seven nasal deformity categories: dorsal hump, crooked nose, boxy tip, pinched tip, droopy tip, saddle nose, and nonallergic nasal obstruction. For each, respondents were asked to rank the three most important anatomic regions to examine from the following: nasal bones, midvault cartilage, skin, radix, facial profile, lip, tip, septum, internal nasal valve, nostrils, inferior and middle turbinates. For each ranked region, up to three important features were chosen. Normalized Attention Scores (NAS) were calculated to determine agreement amongst surgeons. Results: A total of 13 facial plastic and 8 plastic surgeons were invited to participate and completed the questionnaire. All cases had high agreement demonstrated by NAS, with the dorsal hump case exhibiting the greatest variability in responses. Conclusions: In this survey of 21 rhinoplasty surgeons, there was general agreement regarding the most relevant anatomical structures and features, which may provide a conceptual foundation for identifying key exam features for seven common complaints in patients seeking rhinoplasty.
Abstract LB228: DPYSL2 mediates extracellular vesicle-driven reprogramming of the glioblastoma tumor microenvironment
Russo, Marissa, Norton, Emily, Wang, Weiwei, Mukherjee, Shreyartha, Wickland, Daniel P. , Lam, TuKiet, Guerrero-Cázares, Hugo, Russo, Marissa , Norton, Emily S. , TuKiet, L., Guerrero‐Cazares, Hugo

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB228-LB228

10.1158/1538-7445.am2026-lb228 Get It

Abstract The purpose of this study was to identify glioblastoma (GBM) proteins that contribute to the hijacking of the tumor microenvironment through extracellular vesicles (EVs). GBM is the most aggressive primary brain tumor in adults. It presents significant challenges due to its universal recurrence and limited survival rates, exacerbated when its located proximal to the lateral ventricles (LV). The cellular subpopulation of brain tumor-initiating cells (BTICs) plays a pivotal role in tumor initiation and invasiveness, interacting with the microenvironment, particularly the cellular components in the subventricular zone (SVZ) in the LV. We employed an integrated multi-omic strategy combining cell-specific proteomics of EV cargo and whole-cell transcriptomics of EV-treated neural progenitor cells (NPCs) to define mechanisms by which BTICs remodel the tumor microenvironment. Using the TurboID cell-specific protein labeling system, we identified a previously unrecognized repertoire of BTIC-derived proteins selectively packaged into EVs. Among these, DPYSL2 (CRMP2) emerged as a prominent EV cargo as it is implicated in cancer cell migration and invasion. Functionally, exposure of human NPCs to BTIC-derived EVs significantly increased NPC proliferation and migratory capacity in vitro, findings that were recapitulated in vivo following intracranial and intranasal delivery of GBM-derived EVs. To define the molecular basis of these phenotypic changes, we performed RNA sequencing of NPCs following EV treatment. Bioinformatic integration, including ontogenic and pathway enrichment analyses, revealed robust activation of oncogenic signaling pathways, notably JAK/STAT, mTOR, and WNT, accompanied by upregulation of downstream effector genes. Importantly, integrative proteomic-transcriptomic analyses identified DPYSL2 as a mechanistic link between EV cargo and NPC transcriptional reprogramming. Prior studies demonstrate that DPYSL2 can interact with JAK kinases, promoting STAT3 activation and transcription of genes such as Vimentin (VIM) and CALCA, consistent with the transcriptomic changes observed in EV-treated NPCs. Overall, we have identified DPYSL2 as a novel regulator of tumor microenvironment hijacking mediated by extracellular vesicles. This multi-omic approach is the first use of cell-specific proteomics to study extracellular vesicles and the first time pairing this method to identify upstream regulators of transcriptomic changes in neural progenitor cells. Collectively, these findings establish a direct molecular connection between BTIC-derived EV proteins and functional reprogramming of neural progenitor cells, providing mechanistic insight into how glioblastoma exploits developmental programs to promote tumor progression. Citation Format: Marissa Russo, Emily Norton, Weiwei Wang, Shreyartha Mukherjee, Daniel Wickland, TuKiet Lam, Hugo Guerrero-Cazares. DPYSL2 mediates extracellular vesicle-driven reprogramming of the glioblastoma tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB228.